Alivus Life Sciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alivus Life Sciences (formerly Glenmark Life Sciences) reported FY26 revenue of Rs 25,518 million, up 6.9% from Rs 23,869 million in FY25. Profit after tax grew 16.2% to Rs 5,645 million from Rs 4,856 million. The company recognised an exceptional item of Rs 256.57 million due to the statutory impact of new labour codes (gratuity Rs 170 million and compensated absences Rs 86.55 million). EBITDA margin expanded year-over-year. The Board recommended a final dividend of Rs 5 per share (250%). Auditors issued an unmodified opinion. Operating cash flow remained healthy at Rs 5,654 million despite increased working capital outflows (trade receivables up Rs 888 million, inventories up Rs 674 million).
Solid financial performance with double-digit PAT growth and margin expansion. The exceptional charge is non-recurring and regulatory-driven. The dividend payout signals confidence. Shareholders can expect positive sentiment on the back of clean audit opinion and improving profitability.